151 related articles for article (PubMed ID: 36065999)
1. Early switching of tenofovir disoproxil fumarate (TDF) in HIV-infected patients with TDF-induced nephrotoxicity: a prospective study.
Patamatamkul S; Songumpai N; Payoong P; Katavetin P; Putcharoen O
HIV Res Clin Pract; 2022 Aug; 23(1):99-106. PubMed ID: 36065999
[No Abstract] [Full Text] [Related]
2. Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe.
Mashingaidze-Mano R; Bwakura-Dangarembizi MF; Maponga CC; Morse GD; Monera-Penduka TG; Mtisi TJ; Mudzviti T; Mujuru HA
PLoS One; 2020; 15(7):e0235759. PubMed ID: 32634168
[TBL] [Abstract][Full Text] [Related]
3. Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients.
Casado JL; Del Rey JM; Bañón S; Santiuste C; Rodriguez M; Moreno A; Perez-Elías MJ; Liaño F; Moreno S
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):416-22. PubMed ID: 26962850
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study.
Srisopa S; Kornjirakasemsan A; Treebupachatsakul P; Sonthisombat P
Infect Chemother; 2023 Jun; 55(2):226-236. PubMed ID: 37272235
[TBL] [Abstract][Full Text] [Related]
5. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
[TBL] [Abstract][Full Text] [Related]
6. Recovery of renal function after early versus late switching of tenofovir disoproxil fumarate in people living with HIV with renal insufficiency.
Suppadungsuk S; Janepiriyaprayoon P; Sungkanuparph S
Int J STD AIDS; 2022 Mar; 33(4):391-396. PubMed ID: 35143730
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.
Casado JL; Bañón S; Santiuste C; Serna J; Guzman P; Tenorio M; Liaño F; del Rey JM
AIDS; 2016 Jan; 30(2):231-9. PubMed ID: 26684820
[TBL] [Abstract][Full Text] [Related]
8. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G;
J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003
[TBL] [Abstract][Full Text] [Related]
9. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
Hamzah L; Williams D; Bailey AC; Jones R; Ibrahim F; Musso CG; Burling K; Barbini B; Campbell L; Post FA;
HIV Med; 2020 Mar; 21(3):198-203. PubMed ID: 31679186
[TBL] [Abstract][Full Text] [Related]
10. Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD.
Adedeji TA; Adebisi SA; Adedeji NO; Biliaminu SA; Olanrewaju TO
Infect Disord Drug Targets; 2019; 19(1):88-100. PubMed ID: 30027856
[TBL] [Abstract][Full Text] [Related]
11. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
12. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
[TBL] [Abstract][Full Text] [Related]
13. Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
Campbell L; Barbini B; Burling K; Cromarty B; Hamzah L; Johnson M; Jones R; Samarawickrama A; Williams D; Winston A; Post FA;
J Acquir Immune Defic Syndr; 2021 Oct; 88(2):214-219. PubMed ID: 34506361
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
[TBL] [Abstract][Full Text] [Related]
15. Switching to abacavir versus use of a nucleoside-sparing dual regimen for HIV-infected patients with tenofovir-associated renal toxicity.
Casado JL; Santiuste C; Vivancos MJ; Monsalvo M; Moreno A; Perez-Elías MJ; Del Rey JM; Moreno S
HIV Med; 2018 Jun; ():. PubMed ID: 29932293
[TBL] [Abstract][Full Text] [Related]
16. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
[TBL] [Abstract][Full Text] [Related]
17. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
[TBL] [Abstract][Full Text] [Related]
18. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
Vrouenraets SM; Fux CA; Wit FW; Garcia EF; Furrer H; Brinkman K; Hoek FJ; Abeling NG; Krediet RT; Reiss P;
AIDS; 2011 Nov; 25(17):2149-55. PubMed ID: 21857491
[TBL] [Abstract][Full Text] [Related]
19. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
Nishijima T; Kurosawa T; Tanaka N; Kawasaki Y; Kikuchi Y; Oka S; Gatanaga H
AIDS; 2016 Jun; 30(10):1563-71. PubMed ID: 26919734
[TBL] [Abstract][Full Text] [Related]
20. Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya.
Karoney MJ; Koech MK; Njiru EW; Owino Ong'or WD
PLoS One; 2022; 17(9):e0273183. PubMed ID: 36108078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
